European Journal of Inflammation-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2021-10-12 路半弯啊

审稿速度:8.0 | 投稿命中率:75.0
经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利

110 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2021-10-22 MS3221112312

审稿速度:5.0 | 投稿命中率:55.0
经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰

85 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2022-04-06 446402168

请问这个期刊能在pubmed上检索到吗？

66 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2021-10-12 李夏乎瑞

审稿速度:7.0 | 投稿命中率:60.0
不特别着急发表的话，这个期刊还是很值得推荐的

70 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2019-11-06 12368365m31(暂无昵称)

1500美元ljh198637 2019-09-05 00:00:00 发表:
这个期刊需要版面费吗

ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗

163 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2021-12-28 Mia

文章的局限性是什么？

78 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2021-12-28 Mia

是否需要在讨论中说明文章局限性？

62 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2021-10-25 丽日丹枫

审稿速度:4.0
经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花

67 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2021-10-01 Aaron琅琊

分虽然不高，但是还是比较友好的，推荐下

104 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1059739, encodeId=d8c81059e39c1, content=审稿速度:8.0 | 投稿命中率:75.0 经验分享：一篇meta，8月底投，这个月接受，中间返修两次，润色一次，待缴费！希望顺利 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=路半弯啊, createdTime=Tue Oct 12 12:22:25 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062866, encodeId=e4cb106286675, content=审稿速度:5.0 | 投稿命中率:55.0 经验分享：我现在投这个能保证100%命中率。需要认真，逻辑性强，思路清晰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS3221112312, createdTime=Fri Oct 22 09:42:14 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209009, encodeId=145512090091b, content=请问这个期刊能在pubmed上检索到吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bd5a1509712, createdName=446402168, createdTime=Wed Apr 06 16:21:56 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059741, encodeId=9ada1059e4102, content=审稿速度:7.0 | 投稿命中率:60.0 不特别着急发表的话，这个期刊还是很值得推荐的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=132d5594224, createdName=李夏乎瑞, createdTime=Tue Oct 12 12:25:28 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579455, encodeId=b6a15e945562, content=1500美元ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, beContent=ljh198637 2019-09-05 00:00:00 发表: 这个期刊需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=23802406868, createdName=12368365m31(暂无昵称), createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101601, encodeId=eb351101601b2, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101602, encodeId=f83c110160278, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063787, encodeId=21311063e878e, content=审稿速度:4.0 经验分享：投的一篇meta protocol，虽然不是很快，但反馈很有帮助，接受了，撒花, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=丽日丹枫, createdTime=Mon Oct 25 15:42:45 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056788, encodeId=75071056e88b3, content=分虽然不高，但是还是比较友好的，推荐下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=Aaron琅琊, createdTime=Fri Oct 01 14:59:59 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520471, encodeId=bfea5204e17e, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a93f1702660, createdName=nimeide , createdTime=Mon Mar 21 09:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]

2016-03-21 nimeide

审稿速度:1.0 | 投稿命中率:75.0
经验分享：比较友好的期刊，投稿地址为http://eji.sagepub.com/。可投中药药理

374 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务